ArticleThe oncologist2025

COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer.

Camille Mehlman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.